Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration

Abstract

Efficacy of disease modifying drugs (sulfasalazin and methotrexate) as co-therapy with rituximab. Analysis of 10 European registries.

Concentration on long term results, survival on therapy and outcomes dealing with quality of life.

Keywords

• rheumatoid arthritis
• biologic therapy
• rituximab